ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection  by Asselah, Tarik
International HepatologyABT-450 combined with ritonavir, in addition to ABT-333
and ribavirin: A race for an interferon-free regimen
to cure HCV infection
Tarik Asselah
Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, FranceCOMMENTARY ON:
Exploratory study of oral combination antiviral therapy for
hepatitis C. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsa-
decki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G,
Tripathi R, Pilot-Matias T, Bernstein B. N Engl J Med. 2013 Jan
3;368(1):45-53. Copyright  2012 Massachusetts Medical
Society. Abstract reprinted with permission fromMassachusetts
Medical Society.
http://www.ncbi.nlm.nih.gov/pubmed/23281975
Abstract. Background There is a need for interferon-free treatment
regimens for hepatitis C virus (HCV) infection. The goal of this study
was to evaluate ABT-450, a potent HCV NS3 protease inhibitor, com-
bined with low-dose ritonavir (ABT-450/r), in addition to ABT-333, a
nonnucleoside NS5B polymerase inhibitor, and ribavirin, for the
treatment of HCV infection.
Methods: We conducted a 12-week, phase 2a, open-label study
involving patients who had HCV genotype 1 infection without cirrho-
sis. All patients received ABT-333 (400 mg twice daily) and ribavirin
(1000 to 1200 mg per day) and one of two daily doses of ABT-450/r.
Groups 1 and 2 included previously untreated patients; group 1
received 250 mg of ABT-450 and 100 mg of ritonavir, and group 2
received 150 mg and 100 mg, respectively. Group 3, which included
patients who had had a null or partial response to previous therapy
with peginterferon and ribavirin, received daily doses of 150 mg of
ABT-450 and 100 mg of ritonavir. The primary end point was an
undetectable level of HCV RNA from week 4 through week 12
(extended rapid virologic response).
Results: A total of 17 of the 19 patients in group 1 (89%) and 11 of
the 14 in group 2 (79%) had an extended rapid virologic response; a
sustained virologic response 12 weeks after the end of treatment was
achieved in 95% and 93% of the patients, respectively. In group 3, 10
of 17 patients (59%) had an extended rapid virologic response, and 8
(47%) had a sustained virologic response 12 weeks after therapy; 6
patients had virologic breakthrough, and 3 had a relapse. Adverse
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rapid virologic response.events included abnormalities in liver-function tests, fatigue, nausea,
headache, dizziness, insomnia, pruritus, rash, and vomiting.
Conclusions: This preliminary study suggests that 12 weeks of ther-
apy with a combination of a protease inhibitor, a non-nucleoside
polymerase inhibitor, and ribavirin may be effective for treatment
of HCV genotype 1 infection. (Funded by Abbott; ClinicalTrials.gov
number, NCT01306617.)
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Two direct-acting antivirals (DAAs), telaprevir and boceprevir,
are given in combination with pegylated interferon (PegIFN)
and ribavirin to genotype 1 HCV infected patients. PegIFN has
several side effects and many patients are not eligible or have
failed this treatment. Therefore, there is a need to develop an
IFN-free regimen. Ideally, the future IFN-free regimen should
have a high efﬁcacy, favorable safety proﬁle, and high barrier to
resistance [1]. This article is discussing the impressive data from
the IFN-free trial with ABT-450 based regimen [2,3].
ABT-450 is an inhibitor of NS3/4A protease that is metabo-
lized by cytochrome P450 isoform 3A (CYP3A). ABT-450 is co-
administered with ritonavir (ABT-450/r), a CYP3A inhibitor, to
enhance ABT-450 exposure. ABT-450/r is dosed once daily.
ABT-267 is an NS5A inhibitor that is dosed once daily. ABT-333
is an NS5B polymerase non-nucleoside inhibitor dosed twice
daily.
ABT-450 boosted with ritonavir (ABTr), in addition to
ABT-333, and ribavirin for HCV genotype 1 infected patients
(pilot and co-pilot studies)Study design
Impressive results were reported recently from a phase 2a
multicenter open-label study [2]. Groups 1 (n = 19) and 2
(n = 14) included naïve patients, and group 3 (n = 17) included
null (n = 7) or partial responders (n = 10) to previous therapy
(Fig. 1A). All patients received triple therapy with ABT-450r,
ABT-333, and ribavirin, for 12 weeks.13 vol. 59 j 885–888
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Fig. 1. Trial designs and results of studies with ABT-333 based regimen. (A) Phase 2a, multicenter, open-label, trial design [2]. All patients received ABT-333 (400 mg
twice daily) and ribavirin (1000–1200 mg per day) and one of two daily doses of ABT-450/r. Groups 1 and 2 included previously untreated patients; group 1 received
250 mg of ABT-450 and 100 mg of ritonavir, and group 2 received 150 mg and 100 mg, respectively. Group 3, which included patients who had had a null (n = 7) or partial
response (n = 10) to previous therapy with PegIFN/ribavirin, received daily doses of 150 mg of ABT-450 and 100 mg of ritonavir. ABT-450, NS3 protease inhibitor, boosted
with ritonavir (ABT-450/r); ABT-333, non-nucleoside NS5B polymerase inhibitor. (B) Phase 2a, multicenter, open-label, trial results [2]. A total of 17 of the 19 patients in
group 1 (89%) and 11 of the 14 in group 2 (79%) had an extended rapid virologic response; an SVR 12 weeks after the end of treatment was achieved in 95% and 93% of the
patients, respectively. In group 3, 10 of 17 patients (59%) had an extended rapid virologic response, and 8 (47%) had an SVR 12 weeks after therapy; 6 patients had virologic
breakthrough, and 3 had a relapse. HCV RNA <LDQTD or TND (<25 IU/ml); eRVR = extended rapid virological response deﬁned as undetectable HCV RNA from week 4 through
week 12.
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Fig. 2. Aviator study. (A) Trial design [3]. This phase 2b study assesses the safety and efﬁcacy of ABT-450/r (dosed 100/100 mg to 200/100 mg QD), ABT-267 (25 mg QD),
ABT-333 (400 mg BID), and ribavirin in non-cirrhotic treatment-naïve patients and prior PegIFN/ribavirin null responders for 8, 12 or 24 weeks. ABT-450, NS3 protease
inhibitor, boosted with ritonavir (ABT-450/r); ABT-267, NS5A inhibitor; ABT-333, non-nucleoside NS5B polymerase inhibitor. (B) Results from the Aviator study [3]. SVR in
treatment-naïve genotype 1 (GT1) patients and in GT1 null responder patients.
International HepatologyEnd points
The primary end point was the percentage of patients with unde-
tectable HCV-RNA from week 4 through week 12 (extended rapid
virologic response, eRVR). Secondary end points included
patients with HCV-RNA below 25 IU/ml at week 4 (rapid virologic886 Journal of Hepatology 201response, RVR), at week 12, and 12 weeks after the end of treat-
ment (sustained virologic response (SVR)). SVR12 has been dem-
onstrated to be as relevant as SVR24 under PegIFN/ribavirin [4].
COBAS TaqMan HCV Test, version 2.0 was used, with a lower limit
of quantitation of 25 IU/ml and a lower limit of detection of
15 IU/ml.3 vol. 59 j 885–888
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Efﬁcacy in naïve patients
17/19 patients in group 1 and 11/14 in group 2 had an eRVR
(Fig. 1B). None of the patients in group 1 or 2 had virologic break-
through and none who completed treatment had a relapse; all
patients who completed treatment had an SVR12. All 18 patients
who completed treatment in group 1 had undetectable HCV RNA
48 weeks after treatment. 2/13 patients who completed treat-
ment in group 2 discontinued the study after week 12 of fol-
low-up; the other 11 patients had undetectable HCV 48 weeks
after treatment.Efﬁcacy in patients with null or partial response to previous
therapy
6 patients had virologic breakthrough during treatment, including
1 who mistakenly took only 50 mg of ABT-450 daily for the ﬁrst
3 weeks and who never had an HCV RNA lower than 25 IU/ml.
Ten patients had an eRVR. Three patients had a relapse 2 weeks
after treatment, and 8 had an SVR12. 3/7 patients with a null
response and 5/10 with a partial response had SVR12. In most
cases, virologic failure was associated with the emergence of vari-
ants with substitutions in both NS3 and NS5B, at positions known
to confer resistance in vitro to ABT-450 and ABT-333, respectively.Safety
No deaths or serious adverse events occurred. One patient in
group 1 discontinued drugs owing to aminotransferases increase
at week 2. The elevated aminotransferase levels were not associ-
ated with an increased bilirubin level and improved after treat-
ment. The most frequent events were fatigue, nausea, headache,
dizziness, insomnia, pruritus, rash, and vomiting. Most events
were mild. Four adverse events were classiﬁed as severe: fatigue,
pain, vomiting, and hyperbilirubinemia. None of these events led
to drug discontinuation.ABT-450/r, ABT-267, ABT-333 and ribavirin (Aviator study)
The Aviator phase 2b study assesses the safety and efﬁcacy
of ABT-450/r, ABT-267 (NS5A inhibitor), ABT-333, and ribavirin
in non-cirrhotic naïve patients and prior PegIFN/ribavirin
null-responders for 8, 12 or 24 weeks (Fig. 2A) [3]. Results are
summarized in Fig. 2B. For the 12-week triple-DAA regimen with
ribavirin being studied in phase 3 trials: 96% of treatment-naive
patients achieved SVR; and 93% of prior null responders achieved
SVR. Comparable high response rates were obtained in the 12- or
24-week arms, supporting a 12-week treatment duration.
Treatment was well tolerated. Four of 448 patients in the 8- and
12-week arms discontinued treatment because of adverse events.
The most common adverse events were fatigue and headache.Discussion: what have we learned?
First, for naive genotype 1 patients without cirrhosis («easy-
to-cure patients»), this preliminary study suggests that the all-
oral combination of 2 DAAs (ABT-450/r, ABT-333), and ribavirinJournal of Hepatology 201for 12 weeks is associated with a high SVR rate. According to
subtype, no virologic failures occurred among the 26 genotype
1a naïve patients.
Second, this regimen (ABT-450/r, ABT-333, and ribavirin) is
less effective in null or partial responders to previous therapy
(«difﬁcult-to-cure patients»). Extending the treatment duration
beyond 12 weeks may not be an option since most of the virologic
failures occurred during treatment. We do not really understand
why treatments including DAAs are less effective in treatment-
experienced patients when compared to naïve patients, even in
the absence of IFN therapy. Innate immunity may still have a role
in HCV clearance with these DAAs [5]. For previous non-respond-
ers, more potent combination with different compounds may be
needed. The combination of several DAAs (ABT-450/r, ABT-267,
ABT-333, and ribavirin) in non-cirrhotic prior null-responders
provides excellent preliminary results. Moreover, PegIFN may
remain an option in previous non-responders (or as a rescue ther-
apy), since a high SVR rate was achieved when two DAAs were
combined with PegIFN/ribavirin [6].
Third, we will have to wait for more data, with a larger num-
ber of patients, including difﬁcult-to-cure patients with cirrhosis
and previous non-response. Of course, phase 3 studies will pro-
vide more information about safety, effectiveness, and drug-drug
interactions, especially when several new drugs are developed in
the same regimen (and ABT-450 is boosted with ritonavir).Conclusions
Finally, ABT-450-based regimen showed impressive results. It is
unclear whether ribavirin will remain an important agent. For
easy-to-cure patients, ‘‘genotype 1b with mild disease’’, ribavirin
may be not useful. For difﬁcult-to-cure patients, ‘‘cirrhosis with
prior non-response’’, an intensive regimen may be necessary.
The phase 3 program is ongoing. The DAAs in the studies
include ABT-450/r (protease inhibitor and ritonavir), ABT-267
(NS5A inhibitor) and ABT-333 (non-nucleoside polymerase inhib-
itor). Treatment duration will be 12 weeks in non-cirrhotic
patients and 12 or 24 weeks in cirrhotic patients. All patients will
be followed for 48 weeks post-treatment. Co-formulated tablets
of ABT-450/r and ABT-267 will be used in phase 3 trials.
(http://www.clinicaltrials.gov.)
There is a realistic hope for an oral regimen against HCV since
several DAA combinations have reported interesting preliminary
results (increased SVR, low resistance and a preliminary good
safety proﬁle) [7–9]. We have to take into account this important
revolution, but remain cautious and await larger phase 3 data,
especially regarding safety and drug-drug interactions. Finally,
we wish a nice ﬂight to Aviator, and we hope that in the near
future an IFN-free regimen will be available for patients with
HCV infection.Conﬂict of interest
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